PXS-4728 by Syntara for Sleep Disorders: Likelihood of Approval

PXS-4728 is under clinical development by Syntara and currently in Phase II for Sleep Disorders.

Jan 25, 2024 - 18:00

PXS-4728 is under clinical development by Syntara and currently in Phase II for Sleep Disorders.

Read the original article

Tags:

Previous Article

FDA denies approval for Theratechnologies’ tesamorelin F8

Gilead’s Trodelvy lung cancer trial fails to increase survival, leading to a sel...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: Medicare official insists drug price negotiation will consider value of drugs

STAT+: Medicare official insists drug price negotiation...

Apr 25, 2023

Q&A: Chronicling the failures of the U.S. response to Covid

Q&A: Chronicling the failures of the U.S. response to C...

Apr 25, 2023

Bavarian Nordic tops up US smallpox/mpox vaccine stockpile with $156.8m order

Bavarian Nordic tops up US smallpox/mpox vaccine stockp...

Aug 9, 2024